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Protocol
AbstrACt
Introduction Pneumonia is the leading cause of 
childhood morbidity and mortality globally. Introduction of 
the conjugate Haemophilus influenzae B and multivalent 
pneumococcal vaccines in developed countries including 
Australia has significantly reduced the overall burden of 
bacterial pneumonia. With the availability of molecular 
diagnostics, viruses are frequently detected in children 
with pneumonia either as primary pathogens or predispose 
to secondary bacterial infection. Many respiratory 
pathogens that are known to cause pneumonia are 
also identified in asymptomatic children, so the true 
contribution of these pathogens to childhood community-
acquired pneumonia (CAP) remains unclear. Since 
the introduction of pneumococcal vaccines, very few 
comprehensive studies from developed countries have 
attempted to determine the bacterial and viral aetiology 
of pneumonia. We aim to determine the contribution of 
bacteria and viruses to childhood CAP to inform further 
development of effective diagnosis, treatment and 
preventive strategies.
Methods and analysis We are conducting a prospective 
case–control study (PneumoWA) where cases are children 
with radiologically confirmed pneumonia admitted to 
Princess Margaret Hospital for Children (PMH) and controls 
are healthy children identified from PMH outpatient clinics 
and from local community immunisation clinics. The 
case–control ratio is 1:1 with 250 children to be recruited 
in each arm. Nasopharyngeal swabs are collected from 
both cases and controls to detect the presence of viruses 
and bacteria by PCR; pathogen load will be assessed by 
quantitative PCR. The prevalence of pathogens detected 
in cases and controls will be compared, the OR of 
detection and population attributable fraction to CAP for 
each pathogen will be determined; relationships between 
pathogen load and disease status and severity will be 
explored.
Ethics and dissemination This study has been approved 
by the human research ethics committees of PMH, Perth, 
Australia (PMH HREC REF 2014117EP). Findings will 
be disseminated at research conferences and in peer-
reviewed journals.
IntroduCtIon 
Pneumonia is the leading cause of morbidity 
and mortality among young children globally. 
Recent estimates suggest that approximately 
120 million new cases of community-acquired 
pneumonia (CAP) occur each year with nearly 
1 million deaths among children aged <5 
years; most deaths occur in low-resource 
settings.1 2 The burden of childhood CAP in 
strengths and limitations of this study
 ► This is the first case–control study in Australia to 
determine the aetiology and relative contribution of 
respiratory viruses and bacteria to childhood pneu-
monia during the postpneumococcal vaccination 
era.
 ► The study design will estimate how much each 
respiratory pathogen attributes to childhood pneu-
monia at a population level after adjusting for de-
mographic factors, pre-existing chronic medical 
conditions and the presence of other respiratory 
pathogens.
 ► Prospective recruitment of frequency matched cas-
es and controls in each age group will adjust the 
effect of age and pathogen seasonality in causing 
pneumonia in children.
 ► Cases are defined as children with radiological-
ly confirmed pneumonia which reduces the interob-
server variability and increase the generalisability of 
the study data.
 ► Specimens to detect respiratory viruses and bacte-
ria will be collected from the upper respiratory tract 
(nasopharynx) instead of the actual site of infection, 
that is, lower respiratory tract. Pathogens detected 
in nasopharyngeal swab do not necessarily confirm 
the  presence of the same pathogens in the lower 
respiratory tract; however, evidence of these patho-
gens in nasopharynx has been found to be associat-
ed with lower respiratory tract infection in children 
in previous epidemiological studies.
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developed countries is lower (approximately 50 cases per 
1000 child-years), however, CAP remains an important 
public health concern with increasing antibacterial resis-
tance, evidence of replacement disease with non-vaccine 
strains and emergence of new respiratory pathogens.3–5 
In Australia, CAP is an important cause of hospitalisation 
of children with 2–8 hospitalisations per 1000 child-years 
for children <5 years old.6 7 In Western Australia, the inci-
dence is especially high for Aboriginal children who have 
been observed to be at 14 times higher risk of hospitalisa-
tion for CAP than non-Aboriginal children.8 
Aetiology of pneumonia
Identification of causative micro-organisms in childhood 
CAP remains an ongoing challenge, affected by both 
the type of clinical specimens obtained and the testing 
method used. Previous studies have used a variety of spec-
imens to identify the causative pathogen for childhood 
pneumonia, including bronchoalveolar lung fluid, blood, 
nasopharyngeal aspirates, nasopharyngeal swabs and 
pleural fluid (for complicated cases).3 5 A variety of respi-
ratory viruses and bacteria are associated with childhood 
CAP in developed countries9–21 (table 1). Other patho-
gens such as fungi including endemic mycoses are less 
common causes of CAP.22
bacteria
Historically, bacteria were considered to be the most 
important cause of CAP in children globally. Prior to the 
introduction of pneumococcal conjugate vaccines (PCV) 
in developed countries in the early 2000s, Streptococcus 
pneumoniae (the pneumococcus) was the leading bacterial 
pathogen causing CAP, identified in 8%–36% of young chil-
dren with CAP.23 Other bacteria associated with childhood 
pneumonia include both encapsulated and non-typeable 
Haemophilus influenzae, Streptococcus pyogenes, Staphylococcus 
aureus and Moraxella catarrhalis.22 Gram-negative enteric 
bacteria and atypical intracellular bacteria, for example, 
Mycoplasma pneumoniae and Chlamydophila pneumoniae have 
also been reported to cause childhood CAP.22 24 M. pneu-
moniae appears to be detected more commonly among 
school aged than in younger children.25 26 The burden of 
bacterial pneumonia has reduced significantly in Europe, 
the USA and Australia since the introduction of both the 
conjugate H. influenzae B and multivalent PCV into the 
routine immunisation schedule.7 27–30 However, bacteria still 
remain as important causes of pneumonia in many devel-
oping settings where the vaccines have not been introduced 
or recently introduced.31 32
Viruses
With the development of, and more frequent use of 
molecular diagnostics, respiratory viruses are increasingly 
detected among children with pneumonia, particularly 
children <5 years old.3 Among the viruses, respiratory 
syncytial virus (RSV), influenza virus, human parainflu-
enza virus (HPIV), human rhinovirus (HRV) and human 
adenovirus (HAdV) are commonly detected in children 
with pneumonia. The new sensitive molecular tech-
niques have enabled detection of new respiratory viruses 
including human metapneumovirus (HMPV), novel 
human coronavirus (HCoV), human bocavirus and 
emerging strains of influenza virus in childhood CAP.33 
In developed countries, up to 81% of young children with 
CAP have viruses detected in respiratory specimens, with 
RSV the most frequently detected virus in most studies, 
ranging from 7% to 48%.3 4 10 13 15 17 34
Viral–bacterial coinfection
There is evidence that respiratory viruses may have a role 
in facilitating bacterial colonisation, enhancing bacte-
rial infection and/or in enhancing disease severity either 
directly or indirectly. Viruses disrupt the respiratory epithe-
lium barrier and also alter the defence mechanism of host 
epithelium potentially leading to bacterial entrance and 
enabling secondary bacterial infection.35 36 The incidence 
of invasive pneumococcal infection has been observed to be 
higher during increased seasonal activity of some respiratory 
viruses including influenza, RSV, parainfluenza 3 and adeno-
virus.37 38 Further, in clinical trials in South Africa, conju-
gate pneumococcal vaccination resulted in overall decrease 
in virus-associated pneumonia, suggesting interactions 
between respiratory viruses and pneumococcus in causing 
pneumonia in children.39 In Australia, ecological data have 
demonstrated a reduction in viral pneumonia following 
introduction of PCV vaccines.40 RSV has been reported to 
facilitate bacterial colonisation with H. influenzae, Strepto-
coccus pyogenes, Staphylococcus aureus, and M. catarrhalis in the 
nasopharynx of young children with acute respiratory infec-
tion.41 Another study in Australia identified Streptococcus pneu-
moniae, H. influenzae and Staphylococcus aureus in 25% patients 
in intensive care who were admitted with severe influenza 
A infection during 2009 influenza pandemic.42 The patients 
with viral–bacterial coinfection has been reported to suffer 
for treatment failure, longer ventilator support and increased 
likelihood of intensive care unit admission.12 43–45
relationship between bacterial–viral load and severity of 
pneumonia
The relationship between nasopharyngeal pathogen load 
and the disease severity had been previously assessed in 
data from several pneumonia epidemiological studies. 
These studies have demonstrated that nasopharyngeal 
pathogen load could predict the severity of pneumonia in 
children. A study in the USA among infants reported that 
a higher RSV load was associated with longer hospitalisa-
tion, respiratory failure and admission to intensive care 
unit.46 In Vietnam, children with radiological confirmed 
pneumonia had higher pneumococcal load compared 
with children with other respiratory illness and the load 
of pneumococcus was a 15-fold higher in children with 
viral coinfection compared with no viral coinfection.47 
Other studies in Kenya and the Netherlands reported the 
higher nasopharyngeal RSV loads in children with severe 
respiratory infections compared with less severe infec-
tions.48 49
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Table 1 Respiratory bacteria and viruses associated with childhood pneumonia in developed countries
Reference Age Year and country Study participant Specimen
Pathogen (%)
Viruses Bacteria
Michelow et al16 6 weeks–17 years 1999–2000
USA
Children with 
pneumonia
NPA Influenza 21%
RSV 13%
HPIV 1–3 13%
Adenovirus 7%
Rhinovirus 3%
S. pneumoniae 44%
M. pneumoniae 14%
C. pneumoniae (9%)
Don et al11 3 months–16 years 2001–2002
Italy
Children with 
pneumonia
Blood
NPS
Virus: overall 42%
RSV 17%
HPIV 1–3 12%
Influenza 9%
HMPV 5%
Bacteria: overall 44%
M. pneumoniae 27%
S. pneumoniae 18%
H. influenzae 3%
Honkinen et al12 6 months–15 years 2006–2007
Finland
Children with 
pneumonia
Sputum Viruses: overall 72%
Rhinovirus 30%
HBoV 18%
HMPV 14%
HPIV 8%
RSV 7%
Bacteria: overall 91%
S. pneumoniae 50%
H. influenzae 38%
S. aureus 13%
Tajima et al19 1 months–13 years 2001–2002
Japan
Children with 
pneumonia
Blood
NPS
Virus:
RSV 48%
Influenza 22%
HPIV 14%
Bacteria:
S. pneumoniae 36%
H. influenzae 26%
M. pneumoniae 17%
Bacteria–viral coinfection: 18%
Tsolia et al20 5–14 years Not given Children with 
pneumonia
NP wash Viruses: overall 65%
HRV 40%
Adenovirus 12%
HPIV 8%
Influenza 7%
Bacteria: overall 40%
M. pneumoniae 35%
S. pneumoniae 7%
Jain et al13 <18 years 2010–2012
USA
Children with 
pneumonia
Blood
NPS
Viruses: overall 66%
RSV 28%
HRV 27%
HMPV 13%
AdenoV 11%
Influenza 7%
Bacteria: overall 8%
M. pneumoniae 8%
S. pneumoniae 4%
Bacteria–viral coinfection: 7%
Asymptomatic 
children
NPS Rhinovirus 17%
Other viruses: <3%
Juven et al15 <18 years 1993–1995
Finland
Children with 
pneumonia
NPA Viruses: overall 62%
RSV 29%
HRV 24%
HPIV 10%
AdenoV 7%
Influenza 4%
Bacteria: overall 53%
S. pneumoniae 37%
H. influenzae 9%
M. pneumoniae 7%
M. catarrhalis 4%
Bacteria–viral: 30%
Cilla et al10 <3 years 2004–2006
Spain
Children with 
pneumonia
NPA Viruses: overall 67%
RSV 20%
HBoV 14%
HRV 14%
HMPV 12%
HPIV 1–3 11%
Influenza 7%
Cevey-Macherel 
et al9
2 months–5 years 2003–2005
Switzerland
Children with 
pneumonia
Blood
NPA
Viruses: overall 67%
HRV 20%
Influenza 14%
RSV 13%
HMPV 13%
AdenoV 7%
Bacteria: overall 72%
S. pneumoniae 46%
M. pneumoniae 11%
C. pneumoniae 7%
Rhedin et al17 <5 years 2011–2014
Sweden
Children with 
pneumonia
NPA Viruses: overall 81%
RSV 32%
HMPV 23%
HRV 23%
AdenoV 15%
Not tested
Asymptomatic 
children
NPS Viruses: overall 56%
HRV 27%
HBoV 21%
CoronaV 12%
AdenoV 7%%
RSV 6%
Not tested
Continued
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Presence of respiratory pathogens among asymptomatic 
children
Despite a number of studies in developed countries 
designed to explore the aetiology of acute respiratory 
infections in children, including CAP, few included 
healthy/asymptomatic children as controls.13 14 17 18 21 
These studies including healthy controls have identified 
the asymptomatic presence of pathogens known to be 
associated with pneumonia (table 1). Additionally, in 
other epidemiological studies in similar settings, naso-
pharyngeal carriage of respiratory bacteria and viruses 
known to be associated with pneumonia have also been 
reported in healthy children.50–54 Together these findings 
suggest that asymptomatic carriage may be common in 
the healthy population, thereby making interpreting of 
CAP studies more challenging.
significance of this study
Although the PCV have successfully reduced the hospi-
talisation rate with CAP in children in developed coun-
tries, pneumococcus remains as an important pathogen 
because of emergence of non-vaccine serotypes with 
potential to cause severe and complicated pneumonia, 
and empyema.7 With many cases being associated with 
respiratory viruses (table 1), the current immunisation 
strategies focussing exclusively on bacterial pneumonia 
are expected to have modest impacts on further pneu-
monia case reduction. Apart from the annual influenza 
vaccines, to date there are no other licensed vaccine for 
any respiratory viruses that can be used in the community. 
It is critical to understand the relative contribution of 
specific bacterial and viral pathogens to childhood CAP, 
to help inform the development of new therapeutics for 
pneumonia, including antivirals and to support ongoing 
efforts for new preventive strategies such as vaccines 
targeting RSV and parainfluenza which are in advanced 
stages of development. This question constitutes the 
primary aim of this study. Additionally, unveiling rela-
tionships between pathogen load and pathogenicity will 
inform tools for more accurate attribution of the infective 
cause of CAP, allowing better diagnosis and management 
of pneumonia cases using antibiotic and antiviral thera-
pies. Finally, this study will identify emergent serotypes of 
Reference Age Year and country Study participant Specimen
Pathogen (%)
Viruses Bacteria
Spuesens et al18 3 months–16 years 2008–2011
The Netherlands
Children with 
respiratory infections
Blood
NPS
Not tested Bacteria:
S. pneumoniae 28%
M. catarrhalis 23%
M. pneumoniae 16%
H. influenzae 16%
S. aureus 10%
Asymptomatic 
children
Not tested Bacteria:
S. pneumoniae 28%
M. pneumoniae 21%
S. aureus 21%
M. catarrhalis 18%
H. influenzae 15%
Jansen et al14 <6 years 2007–2009
The Netherlands
Children with 
respiratory infections
NW Viruses: overall 72%
RSV 26%
HRV 20%
AdenoV 9%
Influenza 6%
HMPV 6%
Not tested
Asymptomatic 
children
NW Virus: overall 26%
HRV 16%
AdenoV 9%
HCoV 5%
Influenza 3%
RSV 1%
Not tested
Singleton et al21 <3 years 2005–2007
USA
Children with 
respiratory infections
Blood
NPS
Viruses: overall 90%
HRV 44%
AdenoV 30%
RSV 23%
HPIV 18%
HMPV 15%
Bacteria: overall 3%
S. pneumoniae 2%
Asymptomatic 
children
NPS Virus: overall 52%
HRV 33%
AdenoV 16%
HMPV 7%
RSV 4%
HPIV 3%
Not tested
AdenoV, human adenovirus; CoronaV, corona virus; C. pneumoniae, Chlamydophila pneumoniae; H. influenzae, Haemophilus influenzae; HBoV, human bocavirus; 
HPIV, human parainfluenza virus; HMPV, human metapneumovirus; HRV, human rhinovirus; NPA, nasopharyngeal aspirate; NPS, nasopharyngeal  swab; NW, 
nasal  wash; M. catarrhalis, Moraxella catarrhalis; M. pneumoniae, Mycoplasma pneumoniae; RSV, respiratory syncytial virus; S. aureus, Staphylococcus aureus; S. 
pneumoniae, Streptococcus pneumoniae. 
Table 1 Continued 
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pneumococcus causing CAP among vaccinated children, 
informing the design of future pneumococcal vaccines.
The detection of micro-organisms in asymptomatic 
children makes it more challenging to ascertain the exact 
contribution of any pathogen to disease with uncon-
trolled pneumonia aetiological studies. CAP case–control 
studies in children in developing countries are not gener-
alisable to developed countries like Australia where 
health infrastructure, including access to vaccination, is 
much better.21 55–57 Recently, findings from two published 
case–control studies on childhood pneumonia in devel-
oped countries, one in the USA and the other in Sweden, 
have both had limitations (table 1; Jain et al and Rhedin 
et al).13 17 The Swedish study was relatively underpowered 
(93 X-ray confirmed cases and 240 controls) to assess 
attributable risk for a range of viral pathogens and in the 
US study, healthy controls were not enrolled contempo-
raneously or from all study sites which might have biased 
the inference for specific pathogens. The proposed study 
is the first case–control study of pneumonia aetiology in 
Australia in post PCV vaccination era, where 250 radiolog-
ically confirmed hospitalised pneumonia cases (n=250) 
will be compared with 250 age group frequency-matched 
healthy controls for both the presence of respiratory 
pathogens and quantitative load of pathogens. The 
proposed study is expected to address the limitations 
from previous case–control studies through recruitment 
of an appropriate number of cases and controls contem-
poraneously and from the same study sites.
Aim and objectives
The aim of this study is to determine the contribution of 
bacterial and viral respiratory pathogens to CAP among 
West Australian children.
Primary objective
 ► To assess the pathogenicity of respiratory viruses and 
bacteria and pathogen-specific population-attribut-
able risk to radiologically proven CAP in children.
Secondary objectives
To determine the frequency of respiratory virus–bac-
terial coinfection in children with CAP compared 
with healthy children, and to assess the contribution 
of coinfection to clinical outcome and severity.
To compare nasopharyngeal viral and bacterial loads 
in children with CAP compared with healthy children, 
and to assess the importance of pathogen load to dis-
ease status and severity.
To identify the nasopharyngeal quantitative thresh-
old for each pathogen which optimally discriminates 
(sensitivity and specificity) children with CAP from as-
ymptomatic children.
MEthods And AnAlysIs
study design and population
This is a prospective case–control study (named as Pneu-
moWA study) with a case–control ratio of 1:1. Children 
attending publicly funded health services in metropol-
itan Perth, Western Australia are being recruited. Enrol-
ment of children into the study commenced at Princess 
Margaret Hospital for Children (PMH), Perth, Western 
Australia in May 2015.
Both cases and controls are enrolled following the inclu-
sion and exclusion criteria of the study (table 2). Cases 
are defined as children attending PMH with CAP identi-
fied by their treating clinician. The operational definition 
of pneumonia for this study was: (a) the presence of one 
or more of following clinical symptoms: cough, fever or 
increased work of breathing, (b) alveolar consolidation as 
judged by the treating clinician and paediatric radiologist 
and (c) presumed infective aetiology that requiring anti-
biotic therapy. Control group consists of contemporane-
ously healthy children attending PMH outpatient clinics 
or a local community immunisation clinic with no signs of 
respiratory illness.
sample size calculation for the primary objective
A total of 250 cases and 250 controls will be enrolled. The 
power of the study to detect a significantly higher rate of 
pathogen detection among cases versus controls is depen-
dent on the frequency of pathogen detection in healthy 
controls. Using data from previously published literature 
among pneumonia cases and healthy controls,12 51 it was 
estimated that a sample size of 250 pneumonia cases and 
250 healthy controls would provide 80% power to identify 
a significant excess in pathogen detection (lower bound of 
Table 2 Inclusion and exclusion criteria for cases and 
controls in PneumoWA study, Perth, Western Australia
Study 
group Inclusion/exclusion Criteria
Case Inclusion  ► Children <18 years old presenting to 
hospital within the past <36 hours
 ► X-ray confirmed pneumonia
 ► Presumed infective aetiology
 ► A full blood count performed
 ► One nasopharyngeal swab obtained 
within 36 hours of hospital presentation
Exclusion  ► Previously hospitalised within 14 days 
of current presentation
 ► Previously enrolled as a case or 
control in PneumoWA study
Control Inclusion  ► Children <18 years old
 ► One nasopharyngeal swab obtained 
during enrolment
Exclusion  ► Children attending hospital or clinic 
for treatment or follow-up of a 
lower or upper respiratory illness 
(including all respiratory or ENT clinic 
attendees), or proven or probable 
vaccine preventable disease (including 
meningitis, pertussis, measles and 
varicella)
 ► Children attending non-routine/high-
risk immunisation service (including 
vaccine counselling or adverse event 
follow-up)
 ► Hospitalised within 14 days of 
presentation
 ► Previously enrolled as a case or 
control in PneumoWA study
ENT, ear, nose and throat.
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95% CI >1) among cases compared with controls, ranging 
from at least 3% (for influenza) to 15% (for rhinovirus).
Identification and enrolment of study participants
Cases
Cases are identified daily by monitoring presentations to 
the emergency department (ED) and admission records 
at PMH. After assessment against inclusion and exclusion 
criteria, parent(s) are approached by a trained research 
assistant to consent for enrolment followed by data and 
biological specimen collection.
Controls
Controls are enrolled prospectively and contemporane-
ously by trained research staff during attendance at PMH 
outpatient clinics or at the Rheola street immunisation 
clinic, Perth, Western Australia. Parents are approached 
while awaiting for their child’s medical appointment or 
routine immunisation. Controls are frequency matched 
to cases in each age groups (<1 year, 1–4 years, 5–9 years 
and >10 years) by prospectively setting targets for control 
enrolment based on the number of cases enrolled in each 
age group in the preceding 2 weeks.
data collection
Following consent, epidemiological data relating to perti-
nent demographic factors such as age, sex, indigenous 
status, the presence of a smoker in the household, prema-
ture birth and pre-existing chronic health conditions 
such as immunodeficiency, neurological disorder and 
chronic cardiac disease are collected on all study partic-
ipants (table 3) using a standardised paper-based data 
collection form by interviewing the parents. Data on 
clinical management and disease outcome of the cases 
are obtained by reviewing the hospital medical records. 
Patient’s medical record file will be revisited to obtain 
any missing medical information for that illness episode. 
Immunisation record for each child is collected from 
Australian Immunisation Record (AIR). Each partic-
ipant is allocated a unique identification number to 
allow anonymisation. The data are entered onto a secure 
web-based research database (Medrio).
specimen collection
Nasopharyngeal swabs (NPS) are collected from all 
case and controls using a FLOQswab (Copan Diagnos-
tics, Murrieta, California, USA) by trained research 
staff following WHO recommended procedures.58 
After collection, the swab is stored in 1 mL skim milk–
tryptone–glucose–glycerol broth which is suitable for 
storage and transportation of respiratory bacteria and 
viruses.59 60 Other specimens recommended but not 
mandated include blood cultures and EDTA blood for 
pneumococcal PCR. In the setting of pleural effusion, 
culture and pneumococcal PCR is also recommended. 
Despite the sensitivity and specificity of lung aspirate, this 
is not being undertaken in PneumoWA given the invasive 
nature and risk of the procedure.61
Processing, storage and transportation of specimen
After collection, the NPS specimen is kept on ice and 
processed within 4 hour at the research laboratory of the 
PMH Children’s Clinical Research Facility. The NPS spec-
imen is vortexed for 30 s before divided into two aliquots 
with 500 µL each for bacterial and viral assessment, and 
the vials stored at −80°C. Specimens are batched and peri-
odically sent to reference laboratories for PCR testing. 
The NPS specimens are transported to the reference 
laboratories on ice on the same day of testing to avoid an 
additional freeze–thaw cycle.
laboratory analysis
NPS are tested for viral presence and load at PathWest 
Laboratory Medicine WA, Perth, Australia and for bacte-
rial load at research laboratories at the School of Biomed-
ical Science, University of Western Australia, Perth, 
Western Australia.
The respiratory viruses and atypical bacterial patho-
gens such as M. pneumoniae and C. pneumoniae are 
detected by multiplex real-time PCR at PathWest Labo-
ratories (QEII) using previously described primers and 
probes.62 63 In detail, nucleic acid is extracted from the 
NPS using the MagNA Pure 96 System (Roche Applied 
Science, Indianapolis, Indiana, USA). Extracted nucleic 
acids are tested in Applied Biosystems ViiA7 Real-time 
PCR system (ThermoFisher Scientific, Massachusetts, 
USA) for common respiratory virus panel including 
Influenza A/H1N1 and A/H3N2, Influenza B, HPIV 
type 1–3, HMPV and RSV types A and B. Targets for 
HAdv and HCoV OC43, HCoV 229E, HCoV HKU1 and 
HCoV NL63, HRV and atypical bacteria are set up in 
Qiagen Rotor-Gene TaqMan Analysers for Real-Time 
PCR. PCR assays directed at the 5' non-translated region 
of HRV species A–C are used to distinguish rhinovi-
ruses from enterovirus species A–D were adapted from 
Osterback et al64 (Merritt et al,). Quantitative viral load 
is assessed on all NPS specimens that are positive for 
respiratory viruses. The primers, probes and protocols 
for determining the viral load for a range of viral patho-
gens in NPS specimens have been developed by Path-
West (Sikazwe et al, unpublished data). A nucleic acid 
standard is developed using purified plasmid DNA or 
in vitro transcribed RNA, and the concentration of the 
DNA and/or RNA standard is quantified using fluores-
cent dyes. Following this, a standard curve is generated 
from serial 10-fold dilutions of the DNA and/or RNA 
standards mentioned above. The viral load in the NPS 
specimen is quantified by interpolating from the appro-
priate standard curve. The viral load is reported in viral 
copies/mL.
Quantification of bacterial loads in NPS specimen is 
performed using quantitative real-time PCR (qPCR) 
using methods established at UWA School of Biomed-
ical Science (Kirkham et al unpublished data). NPS in 
STGG are centrifuged at high speed to pellet bacteria 
and associated cells, DNA is then extracted from the 
pellet using enzymatic extraction and the QIAamp DNA 
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minikit (Qiagen, Chadstone, VIC, Australia) as previously 
described.65 Real-time qPCR to detect S. pneumoniae, 
S. aureus, M. catarrhalis and non-typeable H. influenzae 
is conducted on the CFX96 real-time PCR detection 
system (Bio-Rad, California, USA) using the primers and 
probes listed in table 4. A standard curve is generated for 
each run for each reference strain. All samples are run 
in duplicate and density is calculated as an average of 
the two measurements. The bacterial load is assessed in 
colony forming units (CFU)/mL which is equivalent to 
Table 3 Demographic and medical information collected from study participants in PneumoWA study, Perth, Western 
Australia
Data parameter
Study group
Cases Controls
Date of birth X X
Gender X X
Indigenous status X X
Risk factors for pneumonia
a. Household smoking contact
b. Prematurity
c. Immunodeficiency/immunosuppression
d. Congenital or chromosomal abnormality
e. Cochlear implants
f. Intracranial shunt
g. Chronic respiratory and cardiac illness
h. Childcare attendance
i. Previous invasive bacterial infection
X X
Clinical data
a. Antibiotics in the past 7 days
b. Antibiotics in the past 24 hours
c. Date of first chest X-ray (this episode)
d. Time of first chest X-ray (this episode)
e. Empyema diagnosed
a. X
b. X
c. X
d. X
e. X
a. X
b. X
Additional clinical data
a. Symptom onset date
b. Symptoms present during illness
c. Weight (kg)
d. Symptoms (yes/no):
i. Cough
ii. Runny nose
iii. Difficulty/rapid breathing
iv. Vomiting
v. Diarrhoea
vi. Rash
vii. Reduced oral intake
viii. Other symptoms
e. Respiratory rate on presentation
f. Auscultatory finding (yes/no/unknown)
i. Wheeze
ii. Crackles/crepitations
g. Highest temperature recorded
h. Hospital admission (yes/no)
i. ICU admission (yes/no)
j. SpO2 on admission and rate of O2 delivery
k. Supplemental O2required (yes/no)
l. Intravenous fluids or supplemental feeds (yes/no)
m. Positive pressure ventilation (yes/no)
n. Length of stay (days)
o. Discharge status (home/transfer/died)
X
Blood results
a. White cell count (first available)
b. Neutrophil count (first available)
c. CRP (first available)
d. Blood culture and PCR results
X
Nasopharyngeal aspirate (if done) results X
Pleural fluid results (if done):
Culture and PCR result
X
CRP, C reactive protein; ICU, intensive care unit; SpO2, oxygen saturation.
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copies/mL assuming one copy of a bacteria would yield 
one colony forming unit.
data analysis plan
The frequency and proportion positive for each respi-
ratory pathogen among both cases and controls will be 
assessed. Where numbers permit, virus subtypes will be 
reported separately. These proportions will be compared 
across the two groups to identify if there are any specific 
pathogens that are detected more frequently among 
cases than among controls. We will report the crude OR 
of detection for each respiratory pathogen among CAP 
cases versus controls. We will also report the adjusted OR 
for each pathogen after adjustment for demographic 
factors (eg, age, sex, the presence of a smoker in the 
household and premature birth), and the presence of 
other pathogens using multivariable logistic regression 
(referred to as model 1). The adjusted OR of detection 
among cases versus controls will be taken to be indicative 
of the pathogenicity of each organism; the higher the OR 
the higher the indicative pathogenicity of that microor-
ganism. Using the proportion of cases infected and the 
adjusted OR for each pathogen, the population level 
attributable fraction of CAP will be calculated using the 
method of Greenland and Drescher.66 The frequency and 
proportion of cases and controls having more than one 
respiratory virus or bacteria detected will be reported. 
Where numbers permit, a multivariable regression model 
will be developed to explore the existence of significant 
pair-wise interactions between respiratory pathogens 
and disease status. Disease severity for the cases will be 
assessed using Respiratory Index of Severity in Children 
score based on Australian children growth standard.67–69 
Where numbers permit, we will explore the relationship 
between detection of specific pathogens and severe 
disease (vs control status) using multivariable logistic 
regression models as described for model 1 (model 2).
We will report the median log-transformed pathogen 
load of each pathogen for cases and controls and compare 
them using student t-test or Mann-Whitney U test method, 
whichever is applicable, to determine if the pathogen 
load is different between cases and controls. A multivari-
able regression analysis (model 3) will be performed to 
determine the odds of being a case for 1 log10 increase in 
pathogen load/mL for each viral and bacterial pathogen 
after adjusting for demographic factors; where numbers 
permit, the same approach will be used to determine 
increase in the odds of severe pneumonia (vs control 
status) (model 4). We will explore receiver–operating 
curve and corresponding area under the curve to find 
the optimal load cut-points (sensitivity and specificity) 
to discriminate CAP cases from controls, and severe CAP 
from non-severe CAP, for each pathogen.14 We will also 
analyse data using classification and regression tree and 
Bayesian network methods as alternative approaches, to 
select thresholds levels for each pathogen load to discrim-
inate between cases and controls. All analyses will be 
performed using STATA software V.13.0.
Ethics and dissemination
Ethics
Written informed consent is obtained from parents and 
assent from children >7 years prior to administration of 
questionnaire and biological specimen collection. The 
risks and benefits related with participating in the study 
are clearly informed to parents and children before 
obtaining the consent. Unique identification number is 
provided to each participant to ensure anonymity and 
Table 4 Primers and probes for detection of respiratory bacterial pathogens by qPCR in PneumoWA study, Perth, Australia
Detected species Primer/probe Sequence (5' to 3')
H. influenzae fucP fwd GCCGCTTCTGAGGCTGG
fucP rev AACGACATTACCAATCCGATGG
fucP probe 6FAM-TCCATTACTGTTTGAAATAC-MGBNFQ
H. influenzae hpd3 fwd GGTTAAATATGCCGATGGTGTTG
hpd3 rev TGCATCTTTACGCACGGTGTA
hpd3 probe HEX-TTGTGTACACTCCGT/ZEN/TGGTAAAAGAACTTGCAC-3C6
S. pneumoniae lytA fwd ACGCAATCTAGCAGATGAAGCA
lytA rev TCGTGCGTTTTAATTCCAGCT
lytA probe 6FAM-TGCCGAAAACGCTTGATACAG-GGAG-BHQ1
M. catarrhalis copB fwd CGTGTTGACCGTTTTGACTTT
copB rev CATAGATTAGGTTACCGCTGACG
copB probe HEX-ACCGACATCAACCCAAGCTTTGG-BHQ1
S. aureus nuc fwd CATCCTAAAAAAGGTGTAGAGA
nuc rev TTCAATTTTMTTTGCATTTTCTACCA
nuc probe HEX-TTTTCGTAAATGCACTTGCTTCAGGACCA-BHQ1
H. influenzae, Haemophilus influenza; M. catarrhalis, Moraxella catarrhalis; S. aureus, Staphylococcus aureus;  S. pneumoniae,  Streptococcus 
pneumoniae. 
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any information collected about a study participant will 
remain confidential. There is no payment or compensa-
tion associated with the participation.
Dissemination
Findings will be disseminated at national and interna-
tional conferences and health symposiums. Manuscripts 
detailing the results of this study will be submitted for 
publication in peer-reviewed journals. Findings from the 
study would describe the attributable risk of specific viral 
and bacterial pathogens in causing childhood pneumonia 
at population level which might help more efficient diag-
nosis and management of lower respiratory tract infec-
tions (LRTI) including pneumonia in children and could 
reduce inappropriate of antibiotics to treat LRTI.
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